Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.

Robert Battat Dana J LukinEllen J ScherlSuresh PolaAnand KumarLauren OkadaLei YangAnjali JainCorey A Siegel

Published in: Inflammatory bowel diseases (2022)

Dose escalation increased drug concentrations and eliminated antibodies with infliximab but not adalimumab. Initial ATI ≤8.55 U/mL was associated with increased efficacy of dose escalation using this assay.

Keyphrases

open label
rheumatoid arthritis
adverse drug
high throughput
drug induced
randomized controlled trial
ulcerative colitis
emergency department
juvenile idiopathic arthritis
single cell
hidradenitis suppurativa